Dimension Therapeutics, a leading rare disease company advancing novel, liver-directed treatments for diverse genetic disorders has announced that it has expanded its Board of Directors with the elections of Georges Gemayel, Ph.D., former Executive Vice President of Genzyme Corporation, and Arlene M. Morris, former CEO of Syndax Pharmaceuticals. Dimension also announced that Donald J. Hayden, Jr., is leaving his position as a member of the Company’s Board of Directors.
“We are very pleased to welcome Georges and Arlene to the Board, each of whom brings exceptional strategic global and operational expertise in building thriving, successful life sciences firms,” said Dr. Annalisa Jenkins. “These individuals have left their mark on the industry, pursuing diverse, highly successful careers as prominent leaders across the Biopharma ecosystem. We are pleased to augment our Board at this time of evolution and growth at Dimension.”
Dimension’s New Board Members
Dr. Gemayel is the chairman of the board of directors of Orphazyme, OxThera, and Enterome Bioscience, and also serves on the boards of the International Institute of New England, Raptor Pharmaceuticals, and Supernus Pharmaceuticals. He was previously a Director of Adolor Corporation, a publicly traded company (acquired by Cubist Pharmaceuticals), a Director at Prosensa (acquired by BioMarin), a Director of Epitherapeutics (acquired by Gilead), and a Director at NPS (acquired by Shire). Dr. Gemayel received his doctorate in pharmacy from St. Joseph University in Beirut, Lebanon, and his Ph.D. in Pharmacology from Paris-Sud University.
Ms. Morris was most recently President and Chief Executive Officer of Syndax Pharmaceuticals, Inc. Previously, she was President and CEO of Affymax, Inc. During her tenure, Ms. Morris led Affymax through the development of peginesatide (Omontys®), a strategic collaboration with Takeda, and its initial public offering. Prior to this, Ms. Morris was the President and Chief Executive Officer of Clearview Projects.
These board appointments follow the announcement of the new CFO and Treasurer, Jean M. Franchi. Ms. Franchi brings more than 20 years of experience building and leading corporate and divisional financial teams from the R&D stage to commercial operations in the public and private pharmaceutical, biotech, and diagnostics sectors. She will report to Annalisa Jenkins, Dimension’s Chief Executive Officer, and her appointment is effective immediately.
Prior to joining Dimension, Ms. Franchi served as Chief Financial Officer at Good Start Genetics, a molecular genetic information company, where she led the finance team, corporate financing activities, and strategic planning from pre-launch through commercialization and generation of product revenues. Prior to her transition to Good Start in 2012, Ms. Franchi spent 16 years at Genzyme Corporation, where she held roles of increasing responsibility as the company transitioned from early market introductions to become an industry leader in rare disease drug development and commercialization. In 2008, she was appointed Senior Vice President of Corporate Finance, responsible for corporate financial reporting and planning prior to acquisition of the company by Sanofi in 2011.